Status:
RECRUITING
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
Lead Sponsor:
Zabeen Mahuwala, MD
Conditions:
Type2 Diabetes
Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Brief Summary
Three pieces of information lead to the basis for this study: 1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy. 2. Increased production of the hormone amylin occurs in indiv...
Detailed Description
Impaired blood flow through microvessels (arterioles and capillaries) leads to irreversible damage to cells within the affected watershed. In addition to hypertension and age, Type-2 diabetes (DMII) i...
Eligibility Criteria
Inclusion
- Subject has been diagnosed with Type-2 Diabetes.
- Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests.
Exclusion
- Subject has not been diagnosed with Type-2 Diabetes.
- Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.
Key Trial Info
Start Date :
February 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2029
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03481283
Start Date
February 5 2018
End Date
January 1 2029
Last Update
January 17 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
UK Robert Straus Behavioral Science Laboratory
Lexington, Kentucky, United States, 40508
2
University of Kentucky - Kentucky Neuroscience Institute
Lexington, Kentucky, United States, 40536